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Abstract
Background: Annexin II heavy chain (also called p36, calpactin I) is lost in prostate cancers and in
a majority of prostate intraepithelial neoplasia (PIN). Loss of annexin II heavy chain appears to be
specific for prostate cancer since overexpression of annexin II is observed in a majority of human
cancers, including pancreatic cancer, breast cancer and brain tumors. Annexin II exists as a
heterotetramer in complex with a protein ligand p11 (S100A10), and as a monomer. Diverse
cellular functions are proposed for the two forms of annexin II. The monomer is involved in DNA
synthesis. A leucine-rich nuclear export signal (NES) in the N-terminus of annexin II regulates its
nuclear export by the CRM1-mediated nuclear export pathway. Mutation of the NES sequence
results in nuclear retention of annexin II.
Results: Annexin II localized in the nucleus is phosphorylated, and the appearance of nuclear
phosphorylated annexin II is cell cycle dependent, indicating that phosphorylation may play a role
in nuclear entry, retention or export of annexin II. By exogenous expression of annexin II in the
annexin II-null LNCaP cells, we show that wild-type annexin II is excluded from the nucleus,
whereas the NES mutant annexin II localizes in both the nucleus and cytoplasm. Nuclear retention
of annexin II results in reduced cell proliferation and increased doubling time of cells. Expression
of annexin II, both wild type and NES mutant, causes morphological changes of the cells. By site-
specific substitution of glutamic acid in the place of serines 11 and 25 in the N-terminus, we show
that simultaneous phosphorylation of both serines 11 and 25, but not either one alone, prevents
nuclear localization of annexin II.
Conclusion: Our data show that nuclear annexin II is phosphorylated in a cell cycle-dependent
manner and that substitution of serines 11 and 25 inhibit nuclear entry of annexin II. Aberrant
accumulation of nuclear annexin II retards proliferation of LNCaP cells.
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Background
Annexins are a family of proteins that have been isolated
from a variety of cells and tissues and involved in diverse
physiological activities. The amino acid sequence of
annexins consists of a variable amino terminal "tail"
domain followed by four or eight conserved repeats. The
common characteristic of the annexins is that they bind to
biological membranes and anionic phospholipids in a
Ca2+-dependent manner through their conserved four or
eight repeats [1]. The unique amino terminal tail of each
annexin confers its functional and regulatory specificity.
Annexin II exists as two forms in the cells, as a heterote-
tramer and as a 36 kD monomer. In the heterotetramer, 2
molecules of annexin II bind to 2 molecules S100A10.
The annexin II tetramer exists in the sub-plasmalemmal
cytoskeleton network in different cells types [2,3], and is
implicated in a number of membrane-related events,
including the Ca2+-dependent regulation of exocytosis in
chromaffin cells and endocytotic pathway [4–6]. It was
shown that the binding of p11 to annexin II could
increase the affinity of annexin II for Ca2+ and account for
exocytosis in adrenergic cells [7]. As a monomer, annexin
II is found in both the cytoplasm and nucleus, but pre-
dominantly in the cytoplasm. Given the difference
between annexin II and p11 expression levels in different
cell types, the heterotetramer and the monomer may have
different functions [8,9]. The function of the annexin II
monomer in the nucleus was suggested by its purification
as part of a primer recognition protein complex that
enhances DNA polymerase α activity in vitro [10,11]. The
role of annexin II in DNA synthesis and cell proliferation
was demonstrated by immunodepletion of annexin II
from Xenopus egg extracts which resulted in the loss of
DNA replication in these extracts [12], and antisense oli-
gonucleotides to annexin II reduced DNA synthesis in
HeLa cells and retarded progression of cells through the
cell cycle [13,14]. Like many other members of annexin
family, annexin II can be phosphorylated in its N-termi-
nus. Serine 25 was reported to be phosphorylated by pro-
tein kinase C (PKC) both in vivo and in vitro, while serine
11 can only be phosphorylated in vitro [15,16]. In addi-
tion to serine 11 and 25, tyrosine 23 is the phosphoryla-
tion site of protein tyrosine kinase (PTK) pp60src,
suggesting a function in cell growth [17]. The effects of Tyr
or Ser phosphorylation on annexin II function are largely
unknown, although previous studies indicate that phos-
phorylation affects the lipid binding characteristics of the
protein. For example, Tyr phosphorylation of annexin II
by pp60src decreases the binding of the protein to phos-
pholipid vesicles at low Ca2+ concentrations [18], whereas
Ser phosphorylation of the protein by protein kinase C
inhibits its ability to aggregate phospholipid vesicles [19].
Annexin II expression is lost in prostate cancers and in a
majority of prostatic intraepithelial neoplasia (PIN) [20].
Loss of annexin II appears to be specific for prostate cancer
because over expression of annexin II is observed in other
human cancers, including lung cancer, pancreatic cancer,
breast cancer and brain tumors [21–39]. We have previ-
ously reported that annexin II is present at high levels in
human and hamster pancreatic cancer cells and tissues
[38,39], and its expression was localized to invasive areas
of the cancer and in metastatic foci.
Recently, a nuclear export signal was identified in the N-
terminal of annexin II, which overlaps the p11 binding
site and is close to the phosphorylation sites of a 60 kD
phosphoprotein encoded by the src oncogene (pp60src)
and protein kinase C [40]. The role of phosphorylation of
annexin II is not understood, and because of the proxim-
ity of the potential phosphorylation sites to the nuclear
export signal, we propose that phosphorylation of these
sites may modulate the nucleo-cytoplasmic distribution
of annexin II. Our data show that phosphorylated
annexin II localizes in the cell nucleus, and that annexin
II phosphorylation and the nuclear retention is cell cycle
dependent. Annexin II is exported from the nucleus in the
annexin II-null LNCaP cells transfected with wild-type
annexin II either transiently or stably, and this nuclear
export is mediated by CRM1 pathway. Ectopic expression
of annexin II results in changes in cell morphology. Accu-
mulation of annexin II in the nucleus of NES mutant sig-
nificantly reduces cell proliferation. Site directed changes
of serines 11 and 25 to glutamic acid prevents nuclear
entry of annexin II.
Results
Cell cycle-dependent phosphorylation and nuclear 
retention of annexin II in cells
The annexin II N-terminus is distinct from the N-termini
of other annexins and contains sites for p11 binding and
phosphorylation by PKC and pp60src. Thus, modifications
in the N-terminus of annexin II may regulate its cellular
function. Recently, a nuclear export signal (NES) was
identified in the N-terminus of annexin II [40]. The NES
overlaps the p11 binding site and one of the PKC phos-
phorylation sites, and it is also in proximity to the PKC
and pp60src phosphorylation sites. Phosphorylation regu-
lates nuclear export of other NES-containing proteins
[41,42]. Cytosolic and nuclear extracts from unsynchro-
nized human K562 cells that express endogenous annexin
II were subjected to SDS-PAGE and immunoblot analysis
to determine whether annexin II in the cell nucleus is
phosphorylated. The results shown in Figure 1 demon-
strate that nuclear annexin II has a slower mobility in the
SDS-PAGE than the cytosolic annexin II. The slower
mobility form is sensitive to calf intestinal alkaline phos-
phatase (CIAP) treatment, which results in a change in gel
mobility. These data suggest that nuclear annexin II is
phosphorylated, and this phosphorylation could regulateBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/10
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the nuclear retention of annexin II. Additionally, we
observed that treatment of cytosolic extract with CIAP
resulted in a protein with faster mobility, suggesting
annexin II exists in multiple phosphorylation states. Pre-
vious reports have described the mono- and diphosphor-
ylated state of annexin II [43], and our data are consistent
with existence of annexin II in these different phosphor-
ylation states.
The activities of many cell cycle regulatory proteins are
controlled both by expression levels and phosphorylation
status. Annexin II expression is cell cycle regulated
[44,45]. We examined if phosphorylation of nuclear
annexin II is cell cycle-dependent. K562 cells were sub-
jected to centrifugal elutriation, a method that isolates
cells according to their different sizes in different cell cycle
phases. The cells in different cell cycle phases were col-
lected, and cell cycle distribution in each of the fractions
from centrifugal elutriation was confirmed by flow cytom-
etry. Nuclear and cytosolic extracts prepared from cells in
different cell cycle phases were subjected to SDS-PAGE
and western blot analysis. Figure 2 shows the cell cycle
dependent phosphorylation and nuclear retention of
annexin II. Phosphorylated annexin II is seen in nuclear
extracts of G1, G1/S and S/G2 cells, but no phosphorylated
annexin II is observed when most of the cells are in S and
G2/M phase of the cell cycle. The appearance of phospho-
rylated annexin II in the nucleus mimics the annexin II
Annexin II is phosphorylated in nuclear extract of K562 cells Figure 1
Annexin II is phosphorylated in nuclear extract of K562 cells. Human K562 cells were fractionated into nuclear 
extract (NE) and cytosolic extract (CE). One aliquot of NE and CE was treated with CIAP prior to SDS-PAGE. Untreated CE 
and NE were subjected to incubation in the phosphatase buffer without CIAP. 20 µg protein from each extract were subjected 
to SDS-PAGE and immunoblotting with anti-annexin II antisera. Positions of the phosphorylated (upper two) and dephosphor-
ylated annexin II are indicated by arrows.
- +      - +
AnxII-P
AnxII
Marker    NE     NE    CE     CE
30kD
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RNA levels during the HeLa cell cycle previously reported
[44]. Curiously, when the cells were in the S/G2 phase of
the cell cycle, we found reappearance of phosphorylated
annexin II. Since Figure 1 shows that the anti-annexin II
antibody can recognize both faster-mobility cytosolic
annexin II and slower-mobility nuclear annexin II, the
absence of annexin II in certain phases of cell cycle cannot
be explained by the modification of annexin II that blocks
the antibody recognition.
Annexin II-null LNCaP cells for the investigation of the 
functions of annexin II
Annexin II is over-expressed in most cancers and cell lines
derived from such cancer tissues. However, annexin II
expression is lost in prostate cancers. Hence, we examined
a panel of established human prostate cancer cell lines to
find an annexin II-null cell line that would serve as a use-
ful model for studying the physiological role of annexin
II. Figure 3 shows a western blot analysis using whole cell
lysates from a panel of prostate cancer cell lines, including
both androgen-responsive (LNCaP) and androgen-unre-
sponsive (PC-3 and DU-145) cell lines, and cell lines used
as positive controls (NIH 3T3 and SkBr-3). High levels of
annexin II is expressed in PC-3, DU-145, NIH 3T3 and
SkBr-3 cells, but no annexin II is detected in LNCaP cells
of different passage numbers tested. LNCaP cells that are
androgen-responsive progress to androgen-unresponsive
upon continuous passages under normal growth condi-
Phosphorylation of nuclear annexin II and cell cycle distribution Figure 2
Phosphorylation of nuclear annexin II and cell cycle distribution. Human K562 cells were subjected to centrifugal elu-
triation followed by flow cytometry to determine the cell cycle distribution of phosphorylated annexin II. Cells enriched in 
each indicated phase were fractionated to cytosolic extract (CE) and nuclear extract (NE). Twenty µg protein from each sam-
ple were subjected to SDS-PAGE followed by immunoblotting with anti-annexin II antibody. Immunoblot of PGK was used as 
an internal control. The flow cytometric profile of each fraction is presented in the upper panels and the percentage of cells in 
each cell cycle phase is indicated below the immunoblot under each fraction.
30KD
AnxII-P
PGK
Marker CE   NE  CE  NE  CE  NE  CE  NE CE  NE  CE  NE
Log           G1       G1/S          S          S/G2     G2/M
AnxII
G1         40              92           45            6          3           10
S            46              5             43            93      44         4
G2/M    14              3             11            2            53         86
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tions [46]. We analyzed if annexin II expression is related
to androgen responsiveness. Annexin II expression was
not observed in androgen-responsive and androgen-unre-
sponsive LNCaP cells, either in the presence or absence of
dihydrotestosterone (DHT) in the growth medium (data
not shown). Northern blot (Figure 4) analysis was per-
formed to determine if the loss of annexin II expression
occurs at the transcriptional or at the translational level.
Figure 4 shows that annexin II message is expressed at a
high level in PC-3 and DU-145 cells. The density of cells
growing in monolayer can also influence the expression of
genes [47], so the LNCaP cells were seeded in either high
or low density and the expression of annexin II gene was
observed. No annexin II expression was detected in
LNCaP cells plated at either high or low density with or
without treatment with DHT. Our data indicate that
annexin II expression is lost at the transcriptional level in
LNCaP cells.
Thus, LNCaP cells, which are annexin II-null, serve as use-
ful recipient cells to investigate the function of exoge-
nously expressed annexin II in the absence of background
from endogenous annexin II.
Export of annexin II from the nucleus involves the CRM1 
pathway
To confirm whether the annexin II-null LNCaP cells regu-
late NES containing proteins by the CRM1 mediated
Immunoblot analysis of annexin II in prostate cancer cells Figure 3
Immunoblot analysis of annexin II in prostate cancer cells. Cell lysates of NIH3T3 (lane 1), SkBr-3 (lane 2), DU-145 
(lane 3), PC-3 (lane 4) and LNCaP (passage 181, lane 5; passage 142, lane 6; passage 92, lane 7; passage 34, lane 8) were sub-
jected to western blot analysis with mouse anti-human monoclonal anti-annexin II antibody as described in materials and meth-
ods. Lane 9 is the protein molecular markers used for SDS-PAGE. The position of annexin II band is indicated on the right side 
of the panel.
1          2           3           4            5          6   7         8        M
36BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/10
Page 6 of 16
(page number not for citation purposes)
nuclear export pathway, we transfected LNCaP cells with
pEGFP-C1 vector, pEGFP-C1-AnxII or pEGFP-C1-AnxII/
L10AL12A, which encode GFP alone, GFP fused to N-ter-
minus of wild-type annexin II (GFP-WT), and GFP fused
to N-terminus of NES mutant annexin II (GFP-NES),
respectively. Confocal microscopy images of transiently
transfected LNCaP cells are shown in Figure 5. The pres-
ence of GFP was detected by auto-fluorescence of GFP
(green). Immunostaining of annexin II was performed
with secondary antibody conjugated to rhodamine (red).
Colocalization of GFP and annexin II results in the
appearance of yellow fluorescence. Figure 5 shows that
both GFP and GFP-fused NES mutant annexin II distrib-
ute equally throughout the cell, whereas the GFP fused
wild-type annexin II is observed only in the cytoplasm,
indicating that the NES of wild type annexin II is still func-
tional. The cellular distribution of wild-type annexin II
without GFP is identical to the GFP fused wild-type
annexin II (data not shown) indicating no effect of GFP
fusion on the cellular distribution of annexin II. Mutation
of the conserved leucines (L10 and L12) of the annexin II
NES results in retention of annexin II in the nucleus.
We established stable clones of LNCaP cells expressing
GFP alone, wild-type annexin II or NES mutant annexin
II. In these stable clones, we examined the distribution of
annexin II by fractionating the cells and preparing
cytosolic and nuclear extracts. These extracts were sub-
Northern blot analysis of annexin II in prostate cancer cells Figure 4
Northern blot analysis of annexin II in prostate cancer cells. Prior to RNA extraction, LNCaP cells of both low level 
and high level of confluence were treated with 10 nM dihydrotestosterone (DHT) for 2 days. 20 µg RNA were extracted from 
PC-3 cells (lane 1), DU-145 cells (lane 2) and LNCaP cells treated with (lanes 3, 6) or without (lanes 4, 5) DHT. [32P]-labeled 
annexin II cDNA was used as probe (Panel A). The location of full length annexin II cDNA is indicated by an arrow on the left 
side of the panel. The membrane from panel A was probed with [32P]-labeled GAPDH cDNA for normalization of the annexin 
II level (Panel B).
A
B
Annexin II
GAPDH
1      2       3      4      5      6
+       - - +
low    high      low      high
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jected to western blot analysis for annexin II. Figure 6
shows the distribution of GFP, GFP-WT and GFP-NES in
LNCaP cells. As expected, there is no annexin II expressed
in the LNCaP cell transfected with vector alone, and also
there is no endogenous annexin II expressed in LNCaP
cells (Figure 6A, lanes 1 and 2). However, in GFP-WT,
cytosolic fraction contains a majority of annexin II (Figure
6A, lanes 3 and 4). GFP-NES was found to distribute
equally between the cytoplasmic and nuclear extracts (Fig-
ure 6, panel A, lanes 5 and 6). In the nuclear extract, the
unphosphorylated and phosphorylated annexin II are
observed. These results are in agreement with data from
K562 cells (Figure 2), as well as previously published lit-
erature [48]. We determined that the slower mobility
band in the nuclear extract is phosphorylated by subject-
ing the nuclear extract to dephosphorylation with potato
acid phosphatase. Figure 6 (panel C) shows that upon
treatment with the phosphatase, the slower mobility band
is shifted to the position corresponding to annexin II in
the cytosolic extracts. These results are consistent with our
observations in K562 cells (Figure 1). We performed
immunoblot analysis of PGK to ensure that nuclear
extracts were devoid of cytosolic contamination (Figure 6,
panel B).
Localization of wild type and NES mutant annexin II in transiently transfected LNCaP cells Figure 5
Localization of wild type and NES mutant annexin II in transiently transfected LNCaP cells. Transiently trans-
fected LNCaP cells expressing GFP alone, GFP-wild type (GFP-WT) annexin II or GFP-NES mutant (GFP-NES) annexin II were 
fixed and subjected to immunocytochemistry with anti-annexin II antibody as described in materials and methods. The images 
were scanned using laser scanning confocal microscope (LSCM). The green color represents auto-fluorescence of GFP, the red 
color represents the rhodamine staining of annexin II antigen-antibody complex, and the yellow color is the overlay of GFP and 
annexin II images. Bar: 25 µm.
GFP              anti-Annexin II           Merge
GFP
GFP-WT
GFP-NESBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/10
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Stable expression of NES-Annexin II retards LNCaP cell 
proliferation
Because nuclear retention of annexin II is cell cycle
dependent, this protein may play a role in regulating cell
cycle progression and cell proliferation. We examined the
effect of exogenous expression of wild type and NES
mutant annexin II on the growth of LNCaP cells. Reex-
pression of annexin II results in significant morphological
changes to the cells (Figure 7). The vector-alone transfec-
tion does not result in any morphological changes. The
vector-alone transfection does not result in any morpho-
logical changes. However, expression of wild-type
annexin II or NES mutant results in the cells taking on a
mesenchymal phenotype. To eliminate clonal variation,
which may occur in stably transfected cancer cells, and the
possibility that NES mutant itself is affecting proliferation
other than nuclear localization, we examined different
clones or NES-transfected LNCaP cells. Data from two
such clones (NES-1 and NES-4) are shown in Figure 8. The
vector transfected cells and wild type annexin II trans-
fected cells underwent cell doubling with a doubling time
of approximately 34 hours as compared to 30 hours for
the untransfected LNCaP cells, whereas the NES-mutant
cells had a doubling time of 48 hours. The inhibition of
cell proliferation by NES mutant annexin II suggests that
abnormal accumulation of annexin II in the nucleus may
lead to deregulation or inhibition of DNA replication. We
compared the cell cycle distribution of logarithmically
Distribution of GFP and GFP-fused wild type or NES mutant annexin II in LNCaP cells Figure 6
Distribution of GFP and GFP-fused wild type or NES mutant annexin II in LNCaP cells. LNCaP cells expressing 
GFP, GFP-wild type annexin II (GFP-WT), and GFP-NES mutant annexin II (GFP-NES) were fractionated into cytosolic extract 
(CE) and nuclear extract (NE). Each extract was subjected to SDS-PAGE and immunoblot with anti-GFP (Panel A) and anti-
PGK antibody (panel B). Cytosolic and nuclear extracts from the GFP-NES cells were subjected to potato acid phosphatase 
(PACP) treatment as described in materials and methods, and an immunoblot analysis was performed for annexin II (Panel C).
GFP       GFP-WT   GFP-NES
GFP-WT Annexin II
GFP
PGK
CE   NE     CE   NE   CE     NE 
A
B
C
GFP-NES mutant annexin II
PACP            - +           - +
CE    CE      NE       NE
GFP-NES
1    2    3    4     5    6 BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/10
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growing LNCaP cells and the three transfectants using
flow cytometry, and observed no changes in the parental
and transfected cells in the distribution of cells in different
cell cycle phases (data not shown). This observation indi-
cated that nuclear retention of NES-mutant annexin II
does not inhibit the growth of LNCaP cells by blocking
the cells at any certain phase of the cell cycle. These obser-
vations are similar to the finding that the expression of
human Cdc6 mutant, HsCdc6E1E2E3, which is exclu-
sively nuclear, inhibits initiation of DNA replication [49].
Site-directed mutagenesis of serines 11 and 25 to glutamic 
acid prevents nuclear entry of annexin II
We examined the role of phosphorylation in the nuclear
entry and export of annexin II. Initial experiments with
exposure of cells to staurosporine, a protein kinase inhib-
itor, in combination with LMB showed no effect of stau-
rosporine on nuclear accumulation of annexin II (data
not shown), indicating that phosphorylation is not
required for annexin II to enter the cell nucleus. To more
specifically address the role of phosphorylation in nuclear
entry and export of annexin II, we examined the effect of
site-directed changes to known phosphoamino acids.
Because serines 11 and 25 are known to be phosphor-
ylated by protein kinase C [50,51], these residues were
mutated to glutamic acid to mimic the negative charge of
a phosphate group, or to alanine to mimic an unphospho-
rylated state. The mutants were constructed as GFP-fusion
proteins and included single mutants (S11A, S11E, S25A,
S25E) or in combination (S11AS25A, S11AS25E,
S11ES25A, S11ES25E). Transfection of LNCaP cells with
these mutants showed no effect on nuclear entry or
CRM1-mediated inhibition of nuclear export in all of the
mutants except the S11ES25E double mutant. Cells har-
boring this double mutation displayed inhibition of
annexin II entry to the nucleus (Figure 9), indicating the
important regulatory role of the serines at 11 and 25 in the
cellular distribution of annexin II. We find annexin II in
the nucleus as a phosphoprotein in a cell cycle-dependent
manner (Figures 1 and 2), so we conclude that serine 11
and 25 are not the phosphorylation sites involved in
nuclear retention of annexin II, and phosphorylation of
other residues may be important in nuclear entry or
export of annexin II. The contribution of other phos-
phoamino acid residues in annexin II to this regulatory
function needs further investigation.
Discussion
Phosphorylation of annexin II can regulate its multiple
functions in the cell. In the N-terminus of annexin II there
are multiple phosphorylation sites suggesting that phos-
phorylation of these residues may regulate annexin II
physiological functions. When primary cultured
chromaffin cells are stimulated by nicotine, annexin II is
phosphorylated by protein kinase C at Ser-25 and
phosphorylation at this residue appears to be a prerequi-
site for the stimulation of Ca2+-dependent secretion by the
annexin II-p11 complex observed in permeabilized chro-
maffin cells [52], indicating that phosphorylation is
involved in regulating the exocytotic function of annexin
II. In resting chromaffin cells, annexin II is in monomeric
form and predominantly exists in cytosol. However, when
the cells are stimulated by nicotine, annexin II forms het-
erotetramer with p11 and restrict its location to the mem-
brane-associated cytoskeleton [53]. The regulatory role of
phosphorylation at tyrosine 23 is less well understood. It
was shown that Tyr-23 can be phosphorylated by pp60src
[17] and the insulin receptor [54], suggesting its role in
growth regulation. Although there is no evidence shown
for the function of Tyr-23 phosphorylation in exocytosis,
we predict that it may not account for the membrane
related processes since Tyr-23 phosphorylation inhibits
the formation of annexin II heterotetramer with p11 [18].
Despite the studies mentioned above regarding the role of
annexin II phosphorylation on its membrane associated
functions, there is no information on the role of
phosphorylation on the nuclear function of annexin II.
Annexin II was identified to be in a multiprotein complex
with DNA polymerase α-primase [11]. We have previ-
ously demonstrated that annexin II plays a role in DNA
synthesis and cell proliferation. Antisense oligonucle-
otides to annexin II reduce DNA synthesis in HeLa cells
and retard progression of cells through the cell cycle [13].
Immunodepletion of annexin II from Xenopus egg extract
results in loss of DNA replication [12]. Replication
extracts made from cells expressing antisense-annexin II
in a regulatable vector do not support SV40 replication in
vitro [14]. Annexin II expression is regulated in the mam-
malian cell cycle [44], and its levels are enhanced in many
cancers [38].
DNA replication is regulated at the level of initiation [55].
The initiation of DNA replication is mediated by a com-
mon set of protein factors and some of these factors are
activated by phosphorylation catalyzed by cyclin-depend-
ent kinase (CDKs) and the Cdc 7 family of protein kinases
[55]. Although the specific substrates of phosphorylation
have not been identified with certainty, the phosphoryla-
tion pattern is definitely cell cycle dependent. Another
important mechanism that regulates cell cycle transition is
nuclear protein export [56–58]. For example, CDC6 pro-
tein, which is essential for initiation of DNA replication,
contains a NES involved in exporting phosphorylated
forms of CDC6 in a cell cycle-dependent manner [49,59].
Cyclin B is exported from the nucleus and degraded when
cells exit mitosis. The N-terminal peptide of annexin II
contains both Ser/Thr phosphorylation sites and a Tyr
phosphorylation site, and these sites are in proximity to
the nuclear export signal (NES). Thus, the activity of
annexin II in the nucleus may be regulated not only by itsBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/10
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expression levels but also by phosphorylation and nuclear
export. In this study, we have demonstrated that nuclear
annexin II is phosphorylated. Interestingly, after CIAP
treatment, nuclear annexin II still migrates slower than
cytosolic annexin II. This observation suggests that
nuclear annexin II may be phosphorylated differently
from that in the cytosol, and nuclear and cytosolic
annexin II may be regulated through different pathways.
Our data also show that the phosphorylation and nuclear
retention of annexin II is cell cycle-dependent. In G1
phase of the cell cycle, annexin II is phosphorylated and
accumulates in the nucleus, whereas in S phase annexin II
is not detected in the nucleus. These findings are consist-
ent with previous reports [44,48] and similar to the obser-
vations that the human CDC6 homolog, HsCDC6,
accumulates in the nucleus in G1 phase, but in S phase it
is phosphorylated and exported from the nucleus [49].
This similarity indicates that phosphorylation may play a
role in the regulation of nuclear entry and export of
annexin II. However, another possibility is that annexin II
may interact with one or more partner proteins and get
transported into the nucleus in a cell-cycle dependent
manner, and the phosphorylation may be just a require-
ment for its function in the nucleus. Unlike HsCDC6,
which contains both NLS and NES, annexin II contains no
NLS that can mediate its entry into the nucleus, so it is
possible that its nuclear entry is through interaction with
a partner protein containing NLS. Our data shows that
annexin II NES mutant is found distributed equally
between the cytosol and the nucleus. Thus, the nuclear
export pathway for annexin II appears to be more active
Morphology of LNCaP cells transfected with wild type annexin II and NES-annexin II Figure 7
Morphology of LNCaP cells transfected with wild type annexin II and NES-annexin II. Untransfected LNCaP and 
stable clones of vector-alone, GFP-WT and GFP-NES cells were cultured as described in materials and methods. Light micros-
copy images of each of the cultures are shown.
GFP-NES GFP
GFP-WT LNCaPBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/10
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than the nuclear entry. We have shown that annexin II is
exported out of the nucleus by the CRM1 dependent
export pathway.
Ectopic expression of NES mutant annexin II results in a
drastic reduction in the proliferation of LNCaP cells with
an associated increase in cell doubling time. This
reduction in cell proliferation may be due to abnormal
presence of annexin II during the S phase of the cell cycle
where it is usually not present (Figure 2). On the other
hand, it is possible that LNCaP cells lack a binding partner
for annexin II in the cell nucleus and this results in
annexin II becoming a negative regulator of cell prolifera-
tion in the prostate cells. LNCaP cells expressing either the
wild-type or the NES mutant change to a more flattened
and elongated morphology, indicating that annexin II
may cause stabilization of the cytoskeleton. Several lines
of evidence suggest that annexin II may be involved in
cytoskeleton regulation. First, annexin II has been shown
to be associated with the cytoskeleton [60]. Second, it has
been suggested that intracellular annexin II heterote-
tramer acts as a link between the cytoskeleton and the
plasma membrane, although the physiological role of this
proposed interaction are unknown [61]. Third, both
annexin II monomer and tetramer can bind F-actin in
vitro, and annexin II tetramer can bundle F-actin [62]. It is
possible that these annexin II molecules may form com-
plexes with p11 underneath plasma membrane and bind
Accumulation of annexin II in the nucleus retards cell proliferation Figure 8
Accumulation of annexin II in the nucleus retards cell proliferation. Parental LNCaP cells and stable clones of vector-
alone (GFP), GFP-WT or GFP-NES mutant annexin II were cultured as described in materials and methods for up to 8 days. 
Two different GFP-NES clones (NES-1 and NES-4) were included. The cell numbers on the indicated days were obtained from 
a standard curve (data not shown) according to the OD570–690 values. The experiment was done in triplicate and the data were 
analyzed using GraphPad Prism 3.0. Cell doubling time was determined for each culture, and the values were: LNCaP (30.32 ± 
2.1 hours), GFP (33.8 ± 4.6 hours), GFP-WT (34.5 ± 5.1 hours) and GFP-NES (48.1 ± 8.3 hours).
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to cytoskeletal molecules and the annexin II heterote-
tramer then stabilize cytoskeleton, which results in the
morphology change of LNCaP cells. The stabilization of
cytoskeleton also accounts for inhibition of cell migra-
tion. Our results are also consistent with recent finding
showing that re-expression of annexin II inhibits prostate
cancer cell migration [63]. Epithelial mesenchymal transi-
tion (EMT) has been estimated to occur in as much as
18% of breast tumors in vivo and the EMT generally
depicts a more aggressive behavior of the tumor cells [64].
The functional consequence of mesenchymal appearance
of annexin II-transfected cells need to be investigated
further.
The annexin II NES overlaps the interaction site for p11.
Binding of p11 targets annexin II to the cell membrane,
and p11 is not localized to the nucleus. Thus, the heterote-
tramer formed by annexin II and p11 is exclusively
cytosolic and has no role in the nucleus. Previous studies
of other proteins containing NES and NLS motifs show
that the proteins are shuttling between cytoplasm and
nucleus until NES and/or NLS is masked either by phos-
phorylation, association with other proteins, or other
modification [65,66]. Phosphorylation of annexin II may
confer a conformational change resulting in lack of recog-
nition by the CRM1-mediated nuclear export pathway.
Alternatively, phosphorylated annexin II can interact with
additional protein factors in the nucleus, and this interac-
tion masks annexin II NES preventing its nuclear export.
Site-directed change of ser11 and ser25 to glutamic acid prevents nuclear entry of annexin II Figure 9
Site-directed change of ser11 and ser25 to glutamic acid prevents nuclear entry of annexin II. GFP-fused annexin 
II containing Ser to Ala or Ser to Glu either singly or in combination were generated as described in materials and methods. 
Transient transfection of LNCaP cells was performed followed by treatment with or without LMB. Confocal microscopic 
observations were made and representative images are shown. Bar: 10 µm.
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The three known phosphorylation sites in the N-terminus
of annexin II, Ser11, Ser25, and Tyr23, were identified
from studies of the heterotetrameric form of annexin II.
The exact phosphorylation sites of the nuclear monomer
of annexin II are not known, and it is possible that other
potential sites are phosphorylated in the nuclear annexin
II. In this study, we have shown that phosphorylation of
both Ser11 and Ser 25 prevents annexin II entry to the
nucleus. Annexin II phosphorylated in its Ser-11 and 25
cannot form a heterotetramer with p11 [16]. However,
diphosphorylated form of annexin II exists as homodimer
instead of as monomer [16]. The formation of annexin II
homodimer devoid of p11 suggests that the phosphoryla-
tion of the heavy chains could induce a head-to-head
association [16]. This kind of dimerization has also been
observed on a monomeric annexin I in placenta [67] and
brain [68]. Thus, this head-to-head dimerization may
account for the inhibition of nuclear entry of the diphos-
phorylated form of annexin II. From these results, we also
conclude that ser11 and ser25 residues are not involved in
the regulation of nuclear retention of annexin II.
Conclusions
Data from our studies show that annexin II localized in
the cell nucleus is phosphorylated in a cell cycle-depend-
ent manner. The entry of annexin II into the nucleus is
prevented by phosphorylation of serines 11 and 25. Stable
expression of the NES mutant annexin II results in
reduced cell proliferation of LNCaP cells. These results
indicate an important role for nuclear annexin II in cell
proliferation and the regulation of nucleo-cytoplasmic
shuttling of annexin II.
Methods
Cell lines and culture conditions
LNCaP cells were cultured in RPMI 1640 containing 7%
fetal bovine serum (FBS) (Gibco-BRL, Rockville, MD),
100 µg/ml penicillin, and 100 µg/ml streptomycin at 37°
in a 5% CO2 cell culture incubator. Plasmids that express
green fluorescence protein (GFP) alone (pEGFP-C1),
GFP-fused wild type annexin II (pEGFP-C1-wild type
annexin II), or GFP-fused NES mutant annexin II with
lysine 10 and 12 mutated to alanine (pEGFP-C1-AnxII
L10A/L12A) were transfected into LNCaP cells using Lipo-
fectamine Plus (Gibco-BRL). Stably transfected cell popu-
lations were generated by culturing cells in the presence of
0.2 mg/ml G418 and subsequent subcloning. K562 cells
were grown in suspension in RPMI 1640 containing 10%
FBS, 2 mM L-glutamine, 100 µg/ml penicillin, and 100
µg/ml streptomycin.
Cell fractionation
K562 cell pellets were rinsed twice with Hank's balanced
salt solution (HBSS) and once with hypotonic buffer (10
mM Tris-HCl, pH 7.5, 10 mM NaCl and 1 mM MgCl2).
Cells were resuspended and held in hypotonic buffer for
2 hours at 4°C. Cells were disrupted with a Dounce
homogenizer, and disruption was monitored by light
microscopy. No intact cells were observed by microscopy
after homogenization. The homogenate was subjected to
centrifugation in a Sorvall SS-34 rotor at 2,000 revs/min
for 30 minutes at 4°C. The supernatant was designated as
cytoplasmic extract (CE). The nuclear pellet was further
rinsed three times with the hypotonic buffer and the
supernatant from each wash was added to the cytoplasmic
extract. The nuclei were resuspended in 0.4 M potassium
phosphate, pH 7.2, 1 mM EDTA, 1 mM dithiothreitol
(DTT) and 10% glycerol and extracted for 1 hour at 4°C.
Following centrifugation in a Sorvall SS-34 rotor at
10,000 g for 30 minutes at 4°C, the supernatant was
collected as nuclear extract (NE). The cytoplasmic and
nuclear extracts were dialyzed against 50 mM potassium
phosphate, pH 7.2, 1 mM DTT, 1 mM EDTA and 10%
glycerol, and stored at minus 80°C until further use.
LNCaP cell transfectants grown in 80% confluency were
harvested, and the cytosolic extract (CE) and nuclear
extract (NE) were obtained using NE-PER Nuclear and
Cytoplasmic Extraction Reagents (PIERCE, Rockford, IL).
Electrophoresis and Immunoblot analyses
Protein extracts were prepared from indicated cells. The
total amount of protein extracts was quantitated using
Bio-Rad BCA protein assay (Pierce). Indicated amount of
protein from each extract was separated by 12% SDS-
PAGE. After electrophoresis, protein was transferred to
polyvinylidene fluoride (PVDF) membranes (Bio-Rad
Hercules CA). The membranes were blocked in 1X Tris
Buffered Saline with 0.01% Tween 20 (1XTTBS) with 7%
powdered milk for one hour at room temperature then
probed with monoclonal anti-human annexin II at
1:5000 dilution (BD Transduction Laboratories) and pol-
yclonal anti-human PGK at 1:2000 dilution overnight at
4°C. Appropriate secondary antibodies conjugated to
horseradish peroxidase (HRP) were used to detect anti-
gen-antibody complexes. Membranes were developed
using ECL plus (Amersham Pharmacia Biotech, UK) and
exposed to films for appropriate amounts of time.
Phosphatase treatment of cytosolic and nuclear extract of 
LNCaP cells expressing GFP-NES mutant annexin II
LNCaP cells expressing GFP-NES were fractionated into
cytosolic and nuclear extracts using NE-PER nuclear and
cytosolic extraction reagents (PIERCE, Rockford IL). The
extracts were concentrated with Centricon-10 centrifugal
concentrator (Millipore Co.), and 10 µg protein was
treated with 0.5 units of potato acid phosphatase (Sigma
Chemical Co.) for 30 minutes at 37°C in 50 mM PIPES
pH 6.0 buffer. The reaction was terminated by adding
SDS-PAGE sample buffer and both the untreated and
treated extracts were subjected to SDS-PAGE.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/10
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Northern blot
Total RNA was extracted using TRIzol standard protocols.
A total of 20 µg RNA was used in northern blot experi-
ments. Annexin II probe was prepared from the vector
pGAF5-1 by the random primer method of labeling with
32P greater than 1 × 108 cpm/µg. Hybridization of the
probe to the membrane was carried out at 42°C overnight
in a water bath. The membrane was stripped and re-
probed with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) probe and its expression was used as a control
to normalize data for annexin II levels.
Immunocytochemistry
LNCaP cells seeded on the glass coverslips were grown to
80% confluency then fixed for 30 minutes in 4% parafor-
maldehyde in phosphate buffered saline (PBS) and
permeabilized in methanol for 10 minutes. After several
rinses with PBS, cells were pretreated with 10% bovine
serum albumin (BSA) in PBS for 3 hours at room temper-
ature to reduce nonspecific staining. Cells were incubated
with monoclonal anti-human annexin II primary anti-
body (BD Transduction Laboratories) at 1:5000 dilution
in PBS containing 3% BSA for 2 hours at room tempera-
ture, washed, and subsequently incubated for 2 hours
with biotinylated secondary antibody (Vector Laborato-
ries, Inc. Burlingame, CA) diluted 1:500 followed by
staining with rhodamine-avidin D (Vector Laboratories
Inc. Burlingame, CA) diluted 1:2000 for 30 minutes. The
coverslips were washed extensively with PBS and
mounted in VECTASHIELD mounting medium for fluo-
rescence (Vector Laboratories Inc. Burlingame, CA). Cells
were visualized on a Zeiss confocal microscope.
Leptomycin B (LMB) treatment of LNCaP cells
LNCaP cells expressing GFP or GFP-wild type annexin II
were grown to 80% confluence on the surface of round
glass coverslips placed in 12-well plates. The cells were
then treated with 20 nM LMB for 2 hours. The cells were
fixed with 4% paraformaldehyde in 1X PBS and observed
under confocal microscopy.
Cell proliferation assay
Cell proliferation was measured using 3-(4,5-cimethylthi-
azol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) cell
proliferation assay. MTT was dissolved in serum-free and
phenol red-free RPMI 1640 at a concentration of 1 mg/ml.
A total of 30,000 cells were seeded into 6-well plates. On
days 2, 4, 6 and 8, cells were incubated with MTT solution
for 3 hours in a CO2 incubator at 37°C. The MTT reagent
was removed and placed in 2.0 ml microcentrifuge tubes
and centrifuged at 14,000 × g for 5 minutes to pellet and
collect any detached cells. The formazan dye was dis-
solved by adding 2.0 ml of 99% isopropanol to each sam-
ple, and the absorbance was read at 570–690 nm using
spectrophotometer. For the standard curve, 20,000 to
140,000 cells were seeded in 6-well plates, and after 24
hours, the cells were treated with MTT and processed as
described above. Data were plotted using Prizm 3.0
(GraphPad Software, San Diego, CA).
Construction of GFP-fused site directed mutants of 
annexin II
GFP fusion proteins with annexin II containing mutations
in the Ser11 and Ser25 were constructed by inserting
mutant annexin II cDNA into the pEGFP-C1 vector. Ser to
Ala and Ser to Glu mutants were generated as previously
reported [43]. Annexin II cDNA was generated by PCR
with primers containing appropriate restriction sites and
inserted into the corresponding restriction sites of the
pEGFP-C1 vector. GFP-fusion constructs of single mutants
(S11A, S25A, S11E, S25E) and double mutants
(S11AS25A, S11AS25E, S11ES25A, S11ES25E) were gen-
erated for use in our experiments.
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